Original Clinical ScienceThree year post heart transplant outcomes of desensitized durable mechanical circulatory support patients
Section snippets
Study population
This study is a single-center prospective, observational analysis to assess the post-transplant outcome of desensitized MCS 201 patients. Among 689 consecutively enrolled patients who underwent HTx between 2010 and 6, 185 (26.8%) patients were bridged with MCS and 49 (7.1%) patients underwent DST. We categorized them into Group A (desensitized MCS patients, n = 21), Group B (desensitized non-MCS patients, n = 28), and Group C (all nondesensitized patients, n = 640). The desensitization
Baseline characteristics of study population
Among 689 consecutively enrolled patients who underwent HTx between 2010 and 2016, 185 patients were bridged with MCS. Type of MCS were left ventricular assisted device (LVAD) (n = 109), total artificial heart (n = 42), biventricular assisted device (n = 31), right ventricular assisted device (n = 2), and para-corporeal ventricular assisted device (n = 1). In this cohort, 49 (7.1%) patients were desensitized (desensitized MCS patients: 21/185 = 11.4%, desensitized non-MCS patients:
Discussion
With the improvement of MCS technology and management strategy, implantation of MCS in advanced heart failure patients increased. According to a recent world-wide registry report, 44.4% of the patients were bridged with MCS before HTx over the past decade.28 Previous studies reported a higher incidence of sensitization in patients supported with MCS.29, 30 Sensitization remains to be an important issue that limits a transplant candidate’s access to an organ, prolongs wait time and increases the
Conclusions
In conclusion, desensitized MCS patients, compared to desensitized non-MCS patients, showed higher PRA reduction after DST, resulting in an expansion of the donor pool. Desensitized MCS patients showed comparable clinical outcomes to nondesensitized control patients in consecutively enrolled contemporary HTx cohort revealing the safety and efficacy of DST. Based on our results, we recommend DST for highly sensitized MCS patients to increase the chances of HTx as MCS patients seem to better
Disclosure statement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (NRF-2021R1F1A1063430), by the Catholic Medical Center Research Foundation (2023) and by the grant from the Korean Society for Transplantation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
D.H.C. received research grants from Amgen, Biocardia, and Mesoblast and has moderate stock interest in
Acknowledgments
The authors express sincere gratitude to Christine Sumbi and other California Heart Center (an affiliate of Cedars-Sinai Smidt Heart Institute) research team members who enabled this long-term comprehensive study.
References (32)
- et al.
The management of antibodies in heart transplantation: an ISHLT consensus document
J Heart Lung Transpl
(2018) - et al.
The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report— - 2019; focus theme: sonor and recipient size match
J Heart Lung Transpl
(2019) - et al.
Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes
J Heart Lung Transpl
(2015) - et al.
Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant
J Heart Lung Transplant
(2016) - et al.
Commentary: the anticlimax of the left ventricular assist devices-associated antibodies
J Thorac Cardiovasc Surg
(2022) - et al.
Desensitization strategies in adult heart transplantation-will persistence pay off?
J Heart Lung Transpl
(2016) - et al.
Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support
J Heart Lung Transpl
(2022) - et al.
Report from a consensus conference on primary graft dysfunction after cardiac transplantation
J Heart Lung Transpl
(2014) - et al.
The International thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-eighth adult heart transplantation report—2021; focus on recipient characteristics
J Heart Lung Transpl
(2021) - et al.
HLA and MICA allosensitization patterns among patients supported by ventricular assist devices
J Heart Lung Transpl
(2013)
Report from a consensus conference on the sensitized patient awaiting heart transplantation
J Heart Lung Transpl
Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant
J Heart Lung Transpl
The past, present and future of heart transplantation
Korean Circ J
Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association
Circulation
Update on heart failure management and future directions
Korean J Intern Med
Left Ventricular Assist Devices (LVADS): history, clinical application and complications
Korean Circ J
Cited by (0)
- 1
Contributed equally to this paper as first authors.